Aligos Therapeutics (NASDAQ:ALGS) Upgraded by Wall Street Zen to Hold Rating

by · The Cerbat Gem

Wall Street Zen upgraded shares of Aligos Therapeutics (NASDAQ:ALGS – Free Report) from a strong sell rating to a hold rating in a research report report published on Sunday.

A number of other brokerages have also weighed in on ALGS. Westpark Capital assumed coverage on shares of Aligos Therapeutics in a report on Thursday, March 26th. They issued a “buy” rating and a $48.00 price target on the stock. Jefferies Financial Group upgraded shares of Aligos Therapeutics to a “strong-buy” rating in a report on Thursday, March 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aligos Therapeutics in a report on Monday, April 20th. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Aligos Therapeutics in a report on Wednesday, March 11th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $41.50.

Check Out Our Latest Research Report on ALGS

Aligos Therapeutics Price Performance

Shares of ALGS opened at $5.71 on Friday. The firm has a market cap of $35.34 million, a PE ratio of -0.66 and a beta of 2.28. The company’s fifty day moving average is $7.02 and its two-hundred day moving average is $8.01. Aligos Therapeutics has a fifty-two week low of $5.12 and a fifty-two week high of $13.69.

Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($2.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.29) by $0.08. The company had revenue of $2.83 million for the quarter, compared to analyst estimates of $0.25 million. Aligos Therapeutics had a negative net margin of 1,919.68% and a negative return on equity of 139.47%. As a group, equities research analysts anticipate that Aligos Therapeutics will post -7.54 earnings per share for the current year.

Hedge Funds Weigh In On Aligos Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Woodline Partners LP acquired a new position in Aligos Therapeutics in the 1st quarter worth $2,602,000. Marshall Wace LLP acquired a new position in Aligos Therapeutics in the 4th quarter worth $2,504,000. Readystate Asset Management LP lifted its holdings in Aligos Therapeutics by 48.5% in the 3rd quarter. Readystate Asset Management LP now owns 203,113 shares of the company’s stock worth $1,991,000 after buying an additional 66,331 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Aligos Therapeutics by 22.8% in the 3rd quarter. Vanguard Group Inc. now owns 171,689 shares of the company’s stock worth $1,683,000 after buying an additional 31,913 shares in the last quarter. Finally, SummitTX Capital L.P. lifted its holdings in Aligos Therapeutics by 6.7% in the 1st quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock worth $1,106,000 after buying an additional 9,375 shares in the last quarter. Institutional investors and hedge funds own 60.43% of the company’s stock.

More Aligos Therapeutics News

Here are the key news stories impacting Aligos Therapeutics this week:

  • Positive Sentiment: Analysts at HC Wainwright maintained a Buy rating and $50 price target on Aligos Therapeutics, and another report said the stock now carries an average analyst recommendation of “Moderate Buy.” Aligos Therapeutics, Inc. (NASDAQ:ALGS) Receives Average Recommendation of “Moderate Buy” from Analysts
  • Neutral Sentiment: HC Wainwright also raised its FY2030 EPS estimate slightly and improved its Q1 2027 EPS outlook, suggesting a somewhat better long-term earnings trajectory.
  • Neutral Sentiment: The same firm left multiple longer-range estimates in place or near prior levels, indicating the updates were more about refining models than changing the overall investment thesis.
  • Negative Sentiment: HC Wainwright cut its near-term earnings estimates for Q2 2026, Q3 2026, Q4 2026, Q2 2027, Q3 2027 and Q4 2027, which likely weighed on sentiment because lower EPS expectations can signal slower progress toward profitability.
  • Negative Sentiment: The biggest near-term downgrade was for FY2026 EPS, with the loss forecast widened, reinforcing concerns that Aligos Therapeutics may burn cash longer than expected.

Aligos Therapeutics Company Profile

(Get Free Report)

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.

Featured Stories